Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

37.04 +0.63 (+1.73%)
Streaming Delayed Price Updated: 11:54 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company... 
Via PredictStreet
Topics Economy
News headline image
Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market
Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded... 
Via MarketMinute
News headline image
The Great Rotation: Small-Caps Break All-Time Highs as Investors Pivot from Mega-Tech
NEW YORK — In a dramatic shift that has redefined the market landscape of 2025, small-cap stocks have surged to historic levels, signaling what many analysts are calling the "Great Rotation." On... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗
Via Stocktwits
News headline image
The Great Rotation: Why the Russell 2000 is Finally Outpacing the Giants in Late 2025
As of mid-December 2025, the long-awaited "Great Rotation" in the financial markets has shifted from a theoretical prediction to a dominant reality. For the better part of the last three years,... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗
Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity. 
Via Stocktwits
News headline image
2 Growth Stocks to Invest $1,000 in Right Now ↗
These stocks have promising assets in their portfolios that could help make their valuations soar in the future. 
Via The Motley Fool
News headline image
1 Bold Prediction for Viking Therapeutics in 2026 ↗
Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it. 
Via The Motley Fool
News headline image
2 Monster Stocks in the Making to Buy and Hold ↗
The next 12 months will tell us more about their prospects. 
Via The Motley Fool
News headline image
My Top 10 Stocks to Buy for 2026 ↗
These players are well-positioned to potentially gain next year -- and over time. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 ↗
These stocks are underperforming the market this year, but that trend may not last for long. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
What&#39;s Up With The Jump In Viking Therapeutics Stock? ↗
Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area and... 
Via Benzinga
News headline image
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area. 
Via The Motley Fool
News headline image
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗
Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector. 
Via Stocktwits
News headline image
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon ↗
For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗
These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run. 
Via The Motley Fool
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
These stocks both have advanced in the double-digits in recent months. 
Via The Motley Fool
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 No-Brainer Healthcare Stocks to Buy Now ↗
These two healthcare stocks scan as bargains right now. 
Via The Motley Fool
News headline image
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation. 
Via Benzinga
News headline image
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play ↗
Canaccord said Viking’s obesity pipeline is worth far more than the current valuation. 
Via Stocktwits
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗
Via Stocktwits
News headline image
AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗
Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61. 
Via Benzinga
Topics Stocks
News headline image
2 Monster Stocks in the Making ↗
There might still be time to get in on the ground floor. 
Via The Motley Fool
News headline image
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗
Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks. 
Via Stocktwits
News headline image
Is There a Future for Viking Therapeutics? ↗
The weight loss drug company was counted out far too early in the summer, but investors are warming to it again. 
Via The Motley Fool
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
News headline image
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross. 
Via Benzinga
News headline image
Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils ↗
Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria. 
Via Benzinga
News headline image
Here's Why Shares in Viking Therapeutics Shot Higher in October ↗
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.